Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug Candidate
November 04, 2021 09:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article...
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
October 06, 2021 08:30 ET
|
Cassava Sciences, Inc.
First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s DiseaseA Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate...
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
September 22, 2021 08:30 ET
|
Cassava Sciences, Inc.
Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12No Behavior Disorders on...
Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
September 09, 2021 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will...
Cassava Sciences Releases a Public Statement Regarding Recent Allegations
September 03, 2021 07:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent...
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
August 27, 2021 11:32 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau...
Cassava Sciences Responds to Allegations
August 25, 2021 06:00 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted...
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
August 24, 2021 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the...
Cassava Sciences Reports Second Quarter 2021 Financial Results
August 03, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
August 02, 2021 19:54 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending...